Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Significant Drop in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) saw a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 109,000 shares, a decline of 33.9% from the December 31st total of 164,900 shares. Based on an average trading volume of 1,800,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 2.7% of the shares of the company are short sold.

Virax Biolabs Group Price Performance

NASDAQ:VRAX opened at $1.69 on Friday. Virax Biolabs Group has a 1 year low of $0.60 and a 1 year high of $9.00. The business has a fifty day moving average of $2.04 and a 200-day moving average of $2.20.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.